🔗 Share this article

Given that the US continues making historic changes to its immunization schedules, a particular individual has emerged in a surprising turn: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by casting doubt on Covid vaccines in the global health crisis and has zeroed in on possible deaths after COVID-19 immunization in her recent time at the FDA.

Planned Overhauls to Childhood Vaccine Program

Agency leaders had intended to unveil major revisions to the childhood immunization program recently, bringing the US with Denmark’s vaccine program, it is understood – a major change that would place the US at odds with many the global community with little proof for improved outcomes. The announcement has been postponed until the coming year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to speak at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth person to head the office this year.

A New Direction at the FDA

Høeg's temporary position could signify a closer partnership between the pharmaceutical and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a increased emphasis upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for discontinuing certain childhood immunization guidelines in the US so as to align more similar to Denmark, a society with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

To date comments, she has persisted in emphasizing on vaccines – traditionally the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Concerns Over Qualifications

The appointee has little discernible experience in medication creation, oversight or management, which has been standard for former heads of the CBER. She has been employed at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in leading a sizeable institution. She is not an expert in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that previous people who ran CBER have had.”

This division has an immense range of responsibilities at the agency, Woodcock emphasized.

“Everybody just pays attention on the novel medication approvals, but the generic drug division approves thousands of generic drugs. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one must be managed,” Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial administrative element to the position, which manages more than 5,000 personnel. “It’s a huge management job, if you perform it correctly,” the former official concluded.

Official Statement and Contentious Policies

In response to questions about Høeg’s qualifications and whether this selection signifies increased cooperation among regulatory chiefs on vaccines, a representative said that the “concerns are based on inaccurate assumptions”.

“Her resume aligns with the duties of her job,” the representative said, noting the period Dr. Høeg spent guiding the agency head on “pharmaceutical safety and regulatory science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg inherits the agency head's new priority voucher program, a contentious rapid medication authorization process that apparently troubled her predecessors. “How are these medications being selected for this expedited pathway? Who is making the calls?” Howard said. “There is a lot of lack of transparency happening at the regulatory body right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent oversight of pharmaceuticals, except for vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more documented, if concerning, past, critics said. She authored a analysis using non-validated volunteer-provided data to determine the frequency of heart inflammation after Covid vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the current government included changing regulations for recently developed shots and halting “unnecessary” immunizations, she said after the election on a online show. At the FDA, Høeg has allegedly floated the idea of excluding young men from receiving Covid vaccines.

“She is an all-around true believer who begins with her preconceived notions and reverse-engineers to retrofit the science in a extremely misleading, dishonest manner,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg joined fellow dissenters, {like|